Accelerate Diagnostics Inc IPO év
Mi az Accelerate Diagnostics Inc IPO év?
A IPO év az Accelerate Diagnostics Inc - 1996
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Accelerate Diagnostics Inc -hoz képest
Mit csinál Accelerate Diagnostics Inc?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
ipo év -hoz hasonló cégek Accelerate Diagnostics Inc
- Shaw Communications nak IPO év 1995 van
- Husky nak IPO év 1995 van
- Transcontinental , Cl B Mv nak IPO év 1995 van
- Mountain Inc nak IPO év 1995 van
- Brookfield Asset Management nak IPO év 1995 van
- ShawCor nak IPO év 1995 van
- Accelerate Diagnostics Inc nak IPO év 1996 van
- BXP nak IPO év 1997 van
- Faro Technologies nak IPO év 1997 van
- Silgan nak IPO év 1997 van
- Warrior Gold nak IPO év 1997 van
- Ryanair Plc nak IPO év 1997 van
- SIGA Technologies Inc nak IPO év 1997 van